727TiP A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3

Authors: G.K. Abou-Alfa, Junbai Fan, Jeong Heo, Y. Arai, J.P. Erinjeri, Christiane Kühl, Riccardo Lencioni, Zheng Ren, Ai Ping Zeng, Brent Evans, Geoffrey L. Cohen, Masatoshi Kudo - Annals of Oncology 2022 cited by 19